Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Burkitt’s lymphoma (BL) can often be cured by intensive chemotherapy, but the toxicity of such therapy precludes its use in the elderly and in patients with endemic BL in developing countries, necessitating new strategies. The normal germinal centre B cell is the presumed cell of origin for both BL and diffuse large B-cell lymphoma (DLBCL), yet gene expression analysis suggests that these malignancies may use different oncogenic pathways. BL is subdivided into a sporadic subtype that is diagnosed in developed countries, the Epstein–Barr-virus-associated endemic subtype, and an HIV-associated subtype, but it is unclear whether these subtypes use similar or divergent oncogenic mechanisms. Here we used high-throughput RNA sequencing and RNA interference screening to discover essential regulatory pathways in BL that cooperate with MYC, the defining oncogene of this cancer. In 70% of sporadic BL cases, mutations affecting the transcription factor TCF3 (E2A) or its negative regulator ID3 fostered TCF3 dependency. TCF3 activated the pro-survival phosphatidylinositol-3-OH kinase pathway in BL, in part by augmenting tonic B-cell receptor signalling. In 38% of sporadic BL cases, oncogenic CCND3 mutations produced highly stable cyclin D3 isoforms that drive cell cycle progression. These findings suggest opportunities to improve therapy for patients with BL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Delmore, J. E., Issa, G. C., Lemieux, M. E., Rahl, P. B., Shi, J., Jacobs, H. M., Kastritis, E., Gilpatrick, T., Paranal, R. M., Qi, J., et al. (2011) · Cell · doi:10.1016/j.cell.2011.08.017 · Cited by 2,813
Self-citationMurre, C., McCaw, P. S., & Baltimore, D. (1989) · Cell · doi:10.1016/0092-8674(89)90682-x · Cited by 2,635
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278
Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization
Diehl, J. A., Cheng, M., Roussel, M. F., & Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.22.3499 · Cited by 2,130
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Zuber, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Sison, E. A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. (2011) · Nature · doi:10.1038/nature10334 · Cited by 1,870
Murre, C., McCaw, P. S., Vaessin, H., Caudy, M., Jan, L. Y., Jan, Y. N., Cabrera, C. V., Buskin, J. N., Hauschka, S. D., Lassar, A. B., et al. (1989) · Cell · doi:10.1016/0092-8674(89)90434-0 · Cited by 1,815
Stromal Gene Signatures in Large-B-Cell Lymphomas
Lenz, G., Wright, G., Dave, S. S., Xiao, W., Powell, J., Zhao, H., Xu, W., Tan, B., Goldschmidt, N., Iqbal, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802885 · Cited by 1,808
Self-citationDalla-Favera, R., Bregni, M., Erikson, J., Patterson, D., Gallo, R. C., & Croce, C. M. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.24.7824 · Cited by 1,773
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
Davis, R. E., Ngo, V. N., Lenz, G., Tolar, P., Young, R. M., Romesser, P. B., Kohlhammer, H., Lamy, L., Zhao, H., Yang, Y., et al. (2010) · Nature · doi:10.1038/nature08638 · Cited by 1,643
Self-citationFrequent mutation of histone-modifying genes in non-Hodgkin lymphoma
Morin, R. D., Mendez-Lago, M., Mungall, A. J., Goya, R., Mungall, K. L., Corbett, R. D., Johnson, N. A., Severson, T. M., Chiu, R., Field, M., et al. (2011) · Nature · doi:10.1038/nature10351 · Cited by 1,614 · cited 10×
“Viable BL cells were quantified by MTS assay following treatment for 4 days with the indicated concentrations of the pan-class I PI(3) kinase inhibitor BKM120.”
BackgroundMethodInfluentialSelf-citation
Cited by
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Swerdlow, S. H., Campo, E., Pileri, S. A., Harris, N. L., Stein, H., Siebert, R., Advani, R., Ghielmini, M., Salles, G. A., Zelenetz, A. D., et al. (2016) · Blood · doi:10.1182/blood-2016-01-643569 · Cited by 7,831
Self-citationPI3K and cancer: lessons, challenges and opportunities
Fruman, D. A., & Rommel, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4204 · Cited by 1,709
Stine, Z. E., Walton, Z. E., Altman, B. J., Hsieh, A. L., & Dang, C. V. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0507 · Cited by 1,375
A compendium of mutational cancer driver genes
Martínez-Jiménez, F., Muiños, F., Sentís, I., Deu-Pons, J., Reyes-Salazar, I., Arnedo-Pac, C., Mularoni, L., Pich, O., Bonet, J., Kranas, H., et al. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0290-x · Cited by 1,296
Wright, G. W., Huang, D. W., Phelan, J. D., Coulibaly, Z. A., Roulland, S., Young, R. M., Wang, J. Q., Schmitz, R., Morin, R. D., Tang, J., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.015 · Cited by 1,169
Self-citationTargeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wilson, W. H., Young, R. M., Schmitz, R., Yang, Y., Pittaluga, S., Wright, G., Lih, C.-J., Williams, P. M., Shaffer, A. L., Gerecitano, J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3884 · Cited by 1,113
Self-citationAukema, S. M., Siebert, R., Schuuring, E., van Imhoff, G. W., Kluin-Nelemans, H. C., Boerma, E.-J., & Kluin, P. M. (2011) · Blood · doi:10.1182/blood-2010-09-297879 · Cited by 678
Self-citationRecurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas
Palomero, T., Couronné, L., Khiabanian, H., Kim, M.-Y., Ambesi-Impiombato, A., Perez-Garcia, A., Carpenter, Z., Abate, F., Allegretta, M., Haydu, J. E., et al. (2014) · Nature Genetics · doi:10.1038/ng.2873 · Cited by 619
Self-citationRevisiting Global Gene Expression Analysis
Lovén, J., Orlando, D. A., Sigova, A. A., Lin, C. Y., Rahl, P. B., Burge, C. B., Levens, D. L., Lee, T. I., & Young, R. A. (2012) · Cell · doi:10.1016/j.cell.2012.10.012 · Cited by 616
“What are the implications for classifying cell states in disease? Significant effort is being devoted to expression profiling cancer cells and these studies use standard normalization methods (Alizadeh et al., 2000; Beer et al., 2002; Berger et al., 2010; Bhattacharjee et al., 2001; Bittner et al., 2000; Golub et al.,…”
Self-citationThe tumour microenvironment in B cell lymphomas
Scott, D. W., & Gascoyne, R. D. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3774 · Cited by 552
Self-citationFarrell, P. J. (2019) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-013023 · Cited by 541
Germinal centres and B cell lymphomagenesis
Basso, K., & Dalla-Favera, R. (2015) · Nature Reviews Immunology · doi:10.1038/nri3814 · Cited by 510
MYC Deregulation in Primary Human Cancers
Kalkat, M., De Melo, J., Hickman, K., Lourenco, C., Redel, C., Resetca, D., Tamachi, A., Tu, W., & Penn, L. (2017) · Genes · doi:10.3390/genes8060151 · Cited by 443
the ICGC MMML-Seq Project (2012) · Nature Genetics · doi:10.1038/ng.2469 · Cited by 440
Targeting B cell receptor signalling in cancer: preclinical and clinical advances
Burger, J. A., & Wiestner, A. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.121 · Cited by 431
Epstein–Barr virus-associated lymphomas
Shannon-Lowe, C., Rickinson, A. B., & Bell, A. I. (2017) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2016.0271 · Cited by 428
Self-citationTargeting pathological B cell receptor signalling in lymphoid malignancies
Young, R. M., & Staudt, L. M. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3937 · Cited by 401
Self-citationA multiprotein supercomplex controlling oncogenic signalling in lymphoma
Phelan, J. D., Young, R. M., Webster, D. E., Roulland, S., Wright, G. W., Kasbekar, M., Shaffer, A. L., Ceribelli, M., Wang, J. Q., Schmitz, R., et al. (2018) · Nature · doi:10.1038/s41586-018-0290-0 · Cited by 398
Self-citationActivating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells
Küçük, C., Jiang, B., Hu, X., Zhang, W., Chan, J. K. C., Xiao, W., Lack, N., Alkan, C., Williams, J. C., Avery, K. N., et al. (2015) · Nature Communications · doi:10.1038/ncomms7025 · Cited by 393
Self-citationMutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing
Morin, R. D., Mungall, K., Pleasance, E., Mungall, A. J., Goya, R., Huff, R. D., Scott, D. W., Ding, J., Roth, A., Chiu, R., et al. (2013) · Blood · doi:10.1182/blood-2013-02-483727 · Cited by 390
Self-citationA recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma
Yoo, H. Y., Sung, M. K., Lee, S. H., Kim, S., Lee, H., Park, S., Kim, S. C., Lee, B., Rho, K., Lee, J.-E., et al. (2014) · Nature Genetics · doi:10.1038/ng.2916 · Cited by 380
Kurtz, D. M., Soo, J., Co Ting Keh, L., Alig, S., Chabon, J. J., Sworder, B. J., Schultz, A., Jin, M. C., Scherer, F., Garofalo, A., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-00981-w · Cited by 374
Self-citation7-Dehydrocholesterol dictates ferroptosis sensitivity
Li, Y., Ran, Q., Duan, Q., Jin, J., Wang, Y., Yu, L., Wang, C., Zhu, Z., Chen, X., Weng, L., et al. (2024) · Nature · doi:10.1038/s41586-023-06983-9 · Cited by 367
Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma
Jiang, L., Gu, Z.-H., Yan, Z.-X., Zhao, X., Xie, Y.-Y., Zhang, Z.-G., Pan, C.-M., Hu, Y., Cai, C.-P., Dong, Y., et al. (2015) · Nature Genetics · doi:10.1038/ng.3358 · Cited by 366
7-Dehydrocholesterol is an endogenous suppressor of ferroptosis
Freitas, F. P., Alborzinia, H., dos Santos, A. F., Nepachalovich, P., Pedrera, L., Zilka, O., Inague, A., Klein, C., Aroua, N., Kaushal, K., et al. (2024) · Nature · doi:10.1038/s41586-023-06878-9 · Cited by 362
Low-Intensity Therapy in Adults with Burkitt's Lymphoma
Dunleavy, K., Pittaluga, S., Shovlin, M., Steinberg, S. M., Cole, D., Grant, C., Widemann, B., Staudt, L. M., Jaffe, E. S., Little, R. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1308392 · Cited by 360
Self-citationThe ID proteins: master regulators of cancer stem cells and tumour aggressiveness
Lasorella, A., Benezra, R., & Iavarone, A. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3638 · Cited by 355
Alternative splicing and related RNA binding proteins in human health and disease
Tao, Y., Zhang, Q., Wang, H., Yang, X., & Mu, H. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01734-2 · Cited by 320
Sha, C., Barrans, S., Cucco, F., Bentley, M. A., Care, M. A., Cummin, T., Kennedy, H., Thompson, J. S., Uddin, R., Worrillow, L., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01314 · Cited by 300
Synergy between PI3K Signaling and MYC in Burkitt Lymphomagenesis
Sander, S., Calado, D. P., Srinivasan, L., Köchert, K., Zhang, B., Rosolowski, M., Rodig, S. J., Holzmann, K., Stilgenbauer, S., Siebert, R., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.06.012 · Cited by 300
Loss of signalling via Gα13 in germinal centre B-cell-derived lymphoma
Muppidi, J. R., Schmitz, R., Green, J. A., Xiao, W., Larsen, A. B., Braun, S. E., An, J., Xu, Y., Rosenwald, A., Ott, G., et al. (2014) · Nature · doi:10.1038/nature13765 · Cited by 295
Self-citationMinard-Colin, V., Brugières, L., Reiter, A., Cairo, M. S., Gross, T. G., Woessmann, W., Burkhardt, B., Sandlund, J. T., Williams, D., Pillon, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.5827 · Cited by 290
New insights into pre-BCR and BCR signalling with relevance to B cell malignancies
Rickert, R. C. (2013) · Nature Reviews Immunology · doi:10.1038/nri3487 · Cited by 288
Signaling through cyclin D-dependent kinases
Choi, Y. J., & Anders, L. (2014) · Oncogene · doi:10.1038/onc.2013.137 · Cited by 278
Pfeifer, M., Grau, M., Lenze, D., Wenzel, S.-S., Wolf, A., Wollert-Wulf, B., Dietze, K., Nogai, H., Storek, B., Madle, H., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1305656110 · Cited by 270
Grande, B. M., Gerhard, D. S., Jiang, A., Griner, N. B., Abramson, J. S., Alexander, T. B., Allen, H., Ayers, L. W., Bethony, J. M., Bhatia, K., et al. (2019) · Blood · doi:10.1182/blood-2018-09-871418 · Cited by 270
Self-citationStructural insights into the functional diversity of the CDK–cyclin family
Wood, D. J., & Endicott, J. A. (2018) · Open Biology · doi:10.1098/rsob.180112 · Cited by 260
Fischer, U., Forster, M., Rinaldi, A., Risch, T., Sungalee, S., Warnatz, H.-J., Bornhauser, B., Gombert, M., Kratsch, C., Stütz, A. M., et al. (2015) · Nature Genetics · doi:10.1038/ng.3362 · Cited by 257
The FOXO1 Transcription Factor Instructs the Germinal Center Dark Zone Program
Dominguez-Sola, D., Kung, J., Holmes, A. B., Wells, V. A., Mo, T., Basso, K., & Dalla-Favera, R. (2015) · Immunity · doi:10.1016/j.immuni.2015.10.015 · Cited by 248
PLCG1 mutations in cutaneous T-cell lymphomas
Vaqué, J. P., Gómez-López, G., Monsálvez, V., Varela, I., Martínez, N., Pérez, C., Domínguez, O., Graña, O., Rodríguez-Peralto, J. L., Rodríguez-Pinilla, S. M., et al. (2014) · Blood · doi:10.1182/blood-2013-05-504308 · Cited by 229
Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands
Gechijian, L. N., Buckley, D. L., Lawlor, M. A., Reyes, J. M., Paulk, J., Ott, C. J., Winter, G. E., Erb, M. A., Scott, T. G., Xu, M., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0010-y · Cited by 222
“Viral supernatants were collected 48 and 72 after transfection, filtered through a 0.22 µm membrane and concentrated 20-fold with Lenti-X Concentrator.”
InfluentialThe Id-protein family in developmental and cancer-associated pathways
Roschger, C., & Cabrele, C. (2017) · Cell Communication and Signaling · doi:10.1186/s12964-016-0161-y · Cited by 207
“The Id3 destructive and/or the TCF3 activating mutations lead to TCF3 activated transcription resulting in pro-survival phosphoinositide 3kinase (PI3K) signaling [267].”
BackgroundTigan, A.-S., Bellutti, F., Kollmann, K., Tebb, G., & Sexl, V (2016) · Oncogene · doi:10.1038/onc.2015.407 · Cited by 204
The Genetic Basis of Hepatosplenic T-cell Lymphoma
McKinney, M., Moffitt, A. B., Gaulard, P., Travert, M., De Leval, L., Nicolae, A., Raffeld, M., Jaffe, E. S., Pittaluga, S., Xi, L., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0330 · Cited by 201
“We compared the frequencies of the most recurrently mutated genes in HSTL to other lymphomas studied by whole exome sequencing including the T cell lymphomas PTCL not otherwise specified (PTCL NOS) (8), angioimmunoblastic T cell lymphoma (AITL) (8,12), cutaneous T cell lymphoma (CTCL) (13,16–18), adult T cell lymphoma…”
Self-citationDubois, S., Viailly, P.-J., Mareschal, S., Bohers, E., Bertrand, P., Ruminy, P., Maingonnat, C., Jais, J.-P., Peyrouze, P., Figeac, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2305 · Cited by 200
“S7), potentially impairing its ability to inactivate TCF3, as shown in Burkitt lymphoma (36).”
BackgroundCo-infections, inflammation and oncogenesis: Future directions for EBV research
Rickinson, A. B. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.04.004 · Cited by 184
Self-citationGerminal center‐derived lymphomas: The darkest side of humoral immunity
Mlynarczyk, C., Fontán, L., & Melnick, A. (2019) · Immunological Reviews · doi:10.1111/imr.12755 · Cited by 179
Aukema, S. M., Kreuz, M., Kohler, C. W., Rosolowski, M., Hasenclever, D., Hummel, M., Kuppers, R., Lenze, D., Ott, G., Pott, C., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.091827 · Cited by 169
Self-citationKaymaz, Y., Oduor, C. I., Yu, H., Otieno, J. A., Ong'echa, J. M., Moormann, A. M., & Bailey, J. A. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0305 · Cited by 120
“In order to better compare BL subtypes, we also analyzed the published RNAseq dataset of sBLs and cell lines (21).”
MethodChiron, D., Martin, P., Di Liberto, M., Huang, X., Ely, S., Lannutti, B. J., Leonard, J. P., Mason, C. E., & Chen-Kiang, S. (2013) · Cell Cycle · doi:10.4161/cc.24928 · Cited by 71
Jäkel, C., Bergmann, F., Toth, R., Assenov, Y., van der Duin, D., Strobel, O., Hank, T., Klöppel, G., Dorrell, C., Grompe, M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01118-x · Cited by 69
Intlekofer, A. M., Joffe, E., Batlevi, C. L., Hilden, P., He, J., Seshan, V. E., Zelenetz, A. D., Palomba, M. L., Moskowitz, C. H., Portlock, C., et al. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0089-0 · Cited by 35
Metadata
- Authors
- Schmitz, R., Young, R. M., Ceribelli, M., Jhavar, S., Xiao, W., Zhang, M., Wright, G., Shaffer, A. L., Hodson, D. J., Buras, E., Liu, X., Powell, J., Yang, Y., Xu, W., Zhao, H., Kohlhammer, H., Rosenwald, A., Kluin, P., Müller-Hermelink, H. K., Ott, G., Gascoyne, R. D., Connors, J. M., Rimsza, L. M., Campo, E., Jaffe, E. S., Delabie, J., Smeland, E. B., Ogwang, M. D., Reynolds, S. J., Fisher, R. I., Braziel, R. M., Tubbs, R. R., Cook, J. R., Weisenburger, D. D., Chan, W. C., Pittaluga, S., Wilson, W., Waldmann, T. A., Rowe, M., Mbulaiteye, S. M., Rickinson, A. B., & Staudt, L. M.
- Venue
- Nature
- Published
- 2012-08-12
- Volume
- 490
- Issue
- 7418
- Pages
- 116-120
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2118028844
- Cited by
- 924
- References
- 45
- FWCI
- 55.70
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.